I thought that was an excellent and very thorough update. Now...

I thought that was an excellent and very thorough update. Now its up to the wider market to digest it and hopefully the price has some upside (SP range of 2c-3c?).

Drug development will take time. Particularly, all the optimisations and the validation studies that will need to be undertaken. Also, tox takes time.

However, progress seems good and there is some scope of revenue generation through the potential partnering opportunities.

It's also good to see Genentech still evaluating - it proves that there is promise in the work PYC undertook for Genentech.

I'm a bit disappointed though that folks still have sell orders for less than 2c, as curent price is too cheap in my view. I continue to believe this Bioshares conference could be the catalyst for some price action. let's see....